Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-07-01FDA Approved: PREGABALIN CAPSULES, CV — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for Pregabalin Capsules, CV from Cipla USA Inc., under ANDA to market this generic pregabalin capsul…
-
FDA approval · 2025-04-30FDA Approved: PREGABALIN — Supplemental Application (Cipla USA, Inc.)
The FDA approved Cipla's supplemental application to market a generic pregabalin product, enabling a generic version of the drug for its app…
-
FDA approval · 2025-04-23FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for venlafaxine hydrochloride submitted by Macleods Pharmaceuticals Limited.
-
FDA approval · 2025-03-28FDA Approved: DULOXETINE DELAYED-RELEASE — Supplemental Application (Breckenridge Pharmaceutical, Inc.)
The FDA approved Breckenridge Pharmaceutical's supplemental ANDA for a duloxetine hydrochloride delayed-release product, making a generic du…
-
FDA approval · 2025-03-13FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for paroxetine hydrochloride (paroxetine) as a generic product under NorthStar Rx LLC's ANDA.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-03-13FDA Approved: BUCAPSOL — Original Application (PANGEA PHARMACEUTICALS, LLC)
FDA approved BUCAPSOL, a generic buspirone hydrochloride product, under an Original Abbreviated New Drug Application by PANGEA PHARMACEUTICA…
-
FDA approval · 2025-03-05FDA Approved: ESCITALOPRAM — Supplemental Application (SOLCO HEALTHCARE US, LLC)
The FDA granted a supplemental approval for escitalopram (generic) from Solco Healthcare US, LLC under an ANDA.
-
FDA approval · 2025-02-28FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, adding regulatory approval for this ge…
-
FDA approval · 2025-02-21FDA Approved: PREGABALIN — Original Application (Torrent Pharmaceuticals Limited)
FDA approved a generic pregabalin product from Torrent Pharmaceuticals Limited (ANDA 206942) to be used for the same indications as the refe…
-
FDA approval · 2025-02-11FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for paroxetine (Padagis US LLC), updating the labeling to reflect expanded indications for the antid…
-
FDA approval · 2025-01-14FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc., confirming regulatory approval for the g…
-
CLINICAL_TRIALS approval · 2025-01-10Clinical Trial Update: Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Clinical trial update indicates that duloxetine, sponsored by Eli Lilly, has been approved for marketing in relation to a compassionate-use …
-
FDA approval · 2024-12-23FDA Approved: PREGABALIN — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for pregabalin filed by Chartwell RX, LLC (ANDA212865).
-
FDA approval · 2024-12-19FDA Approved: PREGABALIN — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved Ascend Laboratories' supplemental application for pregabalin (generic pregabalin).
-
FDA approval · 2024-12-12FDA Approved: PREGABALIN — Supplemental Application (Advagen Pharma Ltd.)
FDA approved the supplemental application for pregabalin from Advagen Pharma Ltd., authorizing the generic product under an ANDA.
-
EMA approval · 2024-11-29EMA Authorised: Duloxetine Zentiva (duloxetine) — Zentiva, k.s.
The EMA authorised Duloxetine Zentiva (duloxetine) from Zentiva, k.s. as an approved medicinal product for neuralgia/diabetic neuropathy, ma…
-
FDA approval · 2024-10-25FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for escitalopram oxalate from Quallent Pharmaceuticals Health LLC, a generic antidepressant.
-
FDA approval · 2024-10-17FDA Approved: CLORAZEPATE DIPOTASSIUM — Supplemental Application (NORTHSTAR RX LLC)
FDA approved a supplemental application for clorazepate dipotassium submitted by NorthStar RX LLC.
-
FDA approval · 2024-10-08FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)
The FDA approved a supplemental application for escitalopram oxalate (escitalopram) submitted by Exelan Pharmaceuticals Inc.
-
FDA approval · 2024-10-07FDA Approved: ESCITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for escitalopram oxalate from Aurobindo Pharma Limited, enabling this generic product to be mark…
-
FDA approval · 2024-10-07FDA Approved: ESCITALOPRAM — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for escitalopram by Accord Healthcare Inc., finalizing a change to a generic escitalopram product.
-
FDA approval · 2024-10-02FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for escitalopram oxalate submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2024-08-29FDA Approved: PAROXETINE — Supplemental Application (Modavar Pharmaceuticals LLC)
The FDA approved a supplemental application for paroxetine from Modavar Pharmaceuticals LLC.
-
FDA approval · 2024-08-28FDA Approved: PREGABALIN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for pregabalin.
-
FDA approval · 2024-08-23FDA Approved: PREGABALIN — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for pregabalin from Solco Healthcare US, LLC, granting approval for changes related to the generic p…